drugset / Trial / NCT02671084

Sevoflurane and Percutaneous Coronary Intervention by Stent

NCT02671084

Phase 4 Terminated 701 enrolled Instituto Dante Pazzanese de Cardiologia
RandomizedParallel-groupDouble-blindTreatment

Summary

Increase in CK-MB after percutaneous coronary angioplasty more than 100% of baseline can represents a problem to the patients resulting in increase of morbidity and mortality. Patients submitted of coronary angioplasty procedures can release in varying degrees of creatine kinase, MB isoform (CK - MB), on the order of 30% of all angioplasty. Possibly patients who will receive sevoflurane experience a higher level of cardiac cell protection with lower incidence in the release of CK - MB values in excess of 100% baseline.

Timeline

Start
2016-02
Primary completion
2020-04
Completion
2020-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Sevoflurane Other / unclassified 3 % Inhaled

Indications